2:06 PM
May 16, 2018
 |  BC Extra  |  Preclinical News

Nanoparticle pretreatment could boost solid tumor CAR T therapy

Research from the University of Washington and the Fred Hutchinson Cancer Research Center suggests preconditioning cancer patients with immunomodulatory nanoparticles could increase the efficacy of CAR T therapies to treat solid tumors.

The main hypothesis as to why CAR Ts have not shown efficacy in solid tumors is because they are overwhelmed by immunosuppressive factors in the tumor microenvironment (see BioCentury Innovations, May 3).

In the paper published in Cancer Research, the researchers engineered a liposomal nanoparticle to...

Read the full 376 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >